Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Spruce Biosciences
Biotech
Spruce halves head count in push to get ex-BioMarin drug to FDA
Spruce took the action days after inking a deal for a former BioMarin rare disease candidate that it plans to file for accelerated approval in 2026.
Nick Paul Taylor
Apr 28, 2025 8:15am
Spruce inks deal for BioMarin asset, plans 2026 approval filing
Apr 15, 2025 10:29am
Spruce drops only drug after 2nd hyperplasia phase 2 fail
Dec 11, 2024 5:00am
Spruce lays off 5th of staff in wake of phase 2 hyperplasia fail
Mar 14, 2024 8:27am
Pfizer taps former CVS exec Denton for CFO role—Chutes & Ladders
Apr 15, 2022 9:30am
Bind's ex-head Hirsch washes up at C4 as CEO—Chutes & Ladders
Sep 11, 2020 9:30am